VEGFA and retinopathy of prematurity: Patients in group 3 in our observations, due to the severity of the ROP process, were treated with combined diode laser therapy with simultaneous administration of ranibizumab, similarly to patients in groups 1 and 2 in whom anti-VEGF was administered 9.75 ± 3.63 days after laser therapy.